Mia Schexnayder-Davis
Primary Care · New Orleans, LANPI 1609254630
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 380 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,466 and has fallen 68.0% since, to $1,110 in 2025. Among primary care clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 380 payments — averaging $25.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Johnson & Johnson$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $3K from 14 others
What the payments were for
- Food & beverage$9,41399%
- Education$931%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 58 | $1,272 |
| Johnson & Johnson | 30 | $1,215 |
| Alkermes, Inc. | 45 | $1,112 |
| Teva Pharmaceuticals USA, Inc. | 53 | $1,044 |
| AbbVie | 50 | $1,022 |
| Otsuka America Pharmaceutical, Inc. | 31 | $1,020 |
| Indivior Inc. | 32 | $726 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $659 |
| Axsome Therapeutics, Inc. | 14 | $445 |
| Lundbeck LLC | 17 | $198 |
| Boston Scientific | 3 | $143 |
| Dexcom, Inc. | 1 | $124 |
| Sanofi | 1 | $119 |
| Lilly USA, LLC | 1 | $103 |
| UCB, Inc. | 1 | $96 |
| Gilead | 3 | $65 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Braeburn Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$896
- ARISTADA$498
- REXULTI$352
- ABILIFY ASIMTUFII$351
- ABILIFY MAINTENA$351
- VRAYLAR$346
- INVEGA TRINZA$267
- CAPLYTA$249
- Auvelity$247
- AUSTEDO$243
- DUPIXENT$237
- INVEGA$125
- ARISTADA INITIO$124
- DEXCOM G6 TRANSMITTER$124
- UZEDY$122
- INVEGA SUSTENNA$120
- SPRAVATO$111
- Austedo XR$110
- MOUNJARO$103
How this compares
$9,506 in reported general payments places this provider in the 95th percentile of 106 primary care providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 56 | $486,357 |
| Invega TrinzaPaliperidone Palmitate | 25 | $170,626 |
| Invega SustennaPaliperidone Palmitate | 47 | $148,047 |
| Abilify MaintenaAripiprazole | 24 | $62,863 |
| AristadaAripiprazole Lauroxil | 13 | $40,616 |
| VraylarCariprazine Hcl | 25 | $32,416 |
| Fluphenazine Decanoate | 34 | $3,250 |
| Olanzapine | 132 | $2,263 |
| Divalproex Sodium ErDivalproex Sodium | 54 | $2,072 |
| Sertraline Hcl | 219 | $2,043 |
| Aripiprazole | 79 | $2,025 |
| Chlorpromazine Hcl | 22 | $2,005 |
| Haloperidol Decanoate | 54 | $1,985 |
| Divalproex Sodium | 68 | $1,796 |
| Quetiapine Fumarate | 94 | $1,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,272 | $486,35756 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $1,215 | $318,67372 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,020 | $62,86324 claims |
| Alkermes, Inc.Aristada | $1,112 | $40,61613 claims |
| AbbVieVraylar | $1,022 | $32,41625 claims |
| Lilly USA, LLCOlanzapine | $103 | $2,263132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 primary care providers in Louisiana.
Other primary care in New Orleans
- Abby WalkerNew Orleans$3K
- Jacob RickollNew Orleans$3K
- Robin FouquetNew Orleans$2K
- Courtney GriffinNew Orleans$2K
- Amanda HillNew Orleans$1K
- Lucienne SimsNew Orleans$913
- Morgan JonesNew Orleans$738
- Lindsey DuffyNew Orleans$683
- Martha CossichNew Orleans$526
- Wendy TaylorShreveport$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.